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Abstract
Background: Lucerastat, an inhibitor of glucosylceramide synthase, has the potential to restore the balance
between synthesis and degradation of glycosphingolipids in glycolipid storage disorders such as Gaucher disease
and Fabry disease. The safety, tolerability, and pharmacokinetics of oral lucerastat were evaluated in two separate
randomized, double-blind, placebo-controlled, single- and multiple-ascending dose studies (SAD and MAD, respectively)
in healthy male subjects.
Methods: In the SAD study, 31 subjects received placebo or a single oral dose of 100, 300, 500, or 1000 mg lucerastat.
Eight additional subjects received two doses of 1000 mg lucerastat or placebo separated by 12 h. In the MAD study,
37 subjects received placebo or 200, 500, or 1000 mg b.i.d. lucerastat for 7 consecutive days. Six subjects in
the 500 mg cohort received lucerastat in both absence and presence of food.
Results: In the SAD study, 15 adverse events (AEs) were reported in ten subjects. Eighteen AEs were reported
in 15 subjects in the MAD study, in which the 500 mg dose cohort was repeated because of elevated
alanine aminotransferase (ALT) values in 4 subjects, not observed in other dose cohorts. No severe or serious
AE was observed. No clinically relevant abnormalities regarding vital signs and 12–lead electrocardiograms
were observed. Lucerastat Cmax values were comparable between studies, with geometric mean Cmax 10.5
(95% CI: 7.5, 14.7) and 11.1 (95% CI: 8.7, 14.2) μg/mL in the SAD and MAD study, respectively, after 1000 mg
lucerastat b.i.d. tmax (0.5 – 4 h) and t1/2 (3.6 – 8.1 h) were also within the same range across dose groups in
both studies. Using the Gough power model, dose proportionality was confirmed in the SAD study for Cmax
and AUC0–∞, and for AUC0–12 in the MAD study. Fed-to-fasted geometric mean ratio for AUC0–12 was 0.93
(90% CI: 0.80, 1.07) and tmax was the same with or without food, indicating no food effect.
Conclusions: Incidence of drug-related AEs did not increase with dose. No serious AEs were reported for any
subject. Overall, lucerastat was well tolerated. These results warrant further investigation of substrate reduction
therapy with lucerastat in patients with glycolipid storage disorders.
SAD study was registered on clinicaltrials.gov under the identifier NCT02944487 on the 24th of October 2016
(retrospectively registered). MAD study was registered on clinicaltrials.gov under the identifier NCT02944474
on the 25th of October 2016 (retrospectively registered).
Trial registration: A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease.
Clinicaltrials.gov: NCT02930655.
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Background
Lysosomal storage disorders (LSDs) are inborn meta-
bolic multisystemic conditions affecting lysosomal func-
tions, characterized by high morbidity and mortality.
LSDs comprise more than 50 rare disorders, affecting
children, adolescents, and adults, and are caused by spe-
cific mutations in genes encoding lysosomal enzymes
and transporters. These genes are responsible for the
degradation of a wide variety of glycosphingolipids, oli-
gosaccharides, proteins and glycoproteins [1]. Among
them, inborn errors of glycosphingolipid (GSL) catabolic
enzymes or transporters, lead to diseases collectively
termed glycosphingolipidoses or glycolipid storage disor-
ders (GLSDs), and include Gaucher disease, Fabry dis-
ease, GM1/GM2 gangliosidoses, Krabbe disease,
metachromatic leukodystrophy, and Niemann-Pick Type
C disease (NP-C) [2]. In GLSDs, partial or complete
deficiency of GSL catabolic enzymes or transporters is
associated with the cytotoxic accumulation of specific
GSLs, which results in dysfunction of various cell types
and damage in multiple organs.
Lucerastat or N-butyldeoxygalactonojirimycin ((2R,3S,
4R,5S)-1-butyl-2-(hydroxylmethyl)piperidine-3,4,5-triol) is
a soluble, low molecular weight, orally available, iminosu-
gar that has the potential to provide substrate reduction
therapy (SRT) for the treatment of GLSDs. The goal of
SRT with oral lucerastat is to inhibit the enzyme glucosyl-
ceramide synthase (GCS) that catalyzes the first commit-
ted step of GSL biosynthesis, thereby reducing the rate of
synthesis of downstream GSLs to restore the intracellular
balance of synthesis, degradation, and transport of GSLs.
The expected net result is a reduction of cytotoxic GSL
levels in tissues, thereby preventing, stabilizing, or revers-
ing the progressive deterioration in function of affected
organs before irreversible damage occurs. SRT has been
established as a safe and efficacious therapeutic modality
with miglustat, another iminosugar, for the treatment of
Gaucher disease Type 1 (GD1) [3, 4] and NP-C [5], and
eliglustat for the treatment of GD1 [6].
Lucerastat inhibits GCS with an inhibitory constant
(Ki) of 10.6 μM using ceramide as an acceptor [7], as
well as the non-lysosomal glucocerebrosidase (GbA2;
EC3.2.1.45) [8]. In addition, lucerastat has no affinity for
lysosomal glucocerebrosidase (GbA1; EC3.2.1.45) [9].
Lucerastat appears to be more selective than miglustat
as it does not inhibit intestinal sucrase-isomaltase, while
it is only a weak inhibitor of intestinal lactase [10]. Des-
pite lucerastat inhibiting the glycosylation of ceramide to
glucosylceramide, it did not increase levels of ceramides
in cultured cells [11].
Lucerastat is able to cross the blood–brain barrier in
line with its pharmacodynamic effect observed in a
mouse model of GM2 gangliosidosis, in which lucerastat
reduced substrate accumulation (GM2) in the brain, and
improved neuromotor performance and increased sur-
vival [12, 13]. In Fabry mice, lucerastat significantly
reduced globotriaosylceramide (Gb3) storage in the
kidney and dorsal root ganglia (data on file).
The safety, tolerability, and pharmacokinetics (PK) of
lucerastat were investigated in separate single- and
multiple-ascending dose (SAD and MAD) studies con-
ducted in healthy male subjects and testing a wide range
of doses. In the MAD study, a group of subjects received
lucerastat either in the presence or absence of food.
Methods
Subjects
Healthy males aged 18–45 years, with a body weight be-
tween 50 and 100 kg, and with a body mass index (BMI)
of 18–29 kg/m2, were eligible for these studies. Subjects
were considered healthy based on medical history, phys-
ical examination, vital signs measurements (blood pres-
sure, heart rate, and body temperature), 12–lead
electrocardiograms (ECG), clinical laboratory tests
(hematology, blood chemistry, and urinalysis), serology
(hepatitis B, hepatitis C, and HIV), alcohol breath test,
and urine drug test, all performed at screening. Subjects
had to use an adequate method of contraception during
the study and for 4 months after the follow-up visit.
Healthy subjects were not eligible if they had used any
prescribed medication within 5 days prior to study entry
in the SAD study and within 2 weeks before starting the
MAD study. Over-the-counter medications were prohib-
ited within 5 days prior to study start. Other exclusion
criteria were: smoking more than ten cigarettes per day,
blood loss > 400 mL in the 12 weeks period preceding
the study, hypersensitivity to any drug, presence or his-
tory of allergy requiring treatment, and existence of any
surgical or medical condition which, in the judgment of
the clinical investigator, might interfere with the absorp-
tion, distribution, metabolism, or excretion of lucerastat.
Subjects also had to refrain from strenuous exercise,
grapefruit juice and alcohol consumption, from 48 h
before admission to the clinical unit until after the
follow-up visit.
Study design
All participants provided written informed consent prior
to enrolment in these studies, which were conducted in
accordance with the Declaration of Helsinki, Good
Clinical Practice, and local regulations. Both studies
were approved by the national health authority of United
Kingdom and the Edinburgh Independent Ethics
Committee for Medical Research. Both studies were
single-center, double–blind, randomized, and placebo-
controlled trials conducted in healthy males.
Thirty-nine subjects took part in the SAD and were
divided in 5 groups: Groups 1 to 4 received a single dose
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of 100, 300, 500, or 1000 mg of oral lucerastat, respect-
ively, and Group 5 received 2 doses of 1000 mg lucera-
stat separated by 12 h. In each group, 6 subjects were to
receive lucerastat and 2 subjects placebo, except for
Group 1 in which only seven subjects were recruited
and one placebo dose was not given. All 39 subjects
completed the study. After a screening visit performed
within 3 weeks prior to dosing, subjects were admitted
to the clinic the day before lucerastat administration
(Day −1). Subjects received lucerastat in fasted condition
in the morning of Day 1. Subjects from Group 1 to 4
were discharged the day after lucerastat intake (Day 2),
subjects from Group 5 stayed an additional night at the
study site. All subjects returned to the clinical site for a
follow-up visit on Day 7. Progression to the next dose
group was allowed only after review of all safety data.
In the MAD study, 27 subjects in three different
cohorts were planned with, in each cohort, 6 subjects
receiving 200, 500, or 1000 mg lucerastat b.i.d. and 3
subjects receiving placebo. In view of some safety find-
ings, the 500 mg dose was repeated to include 10 add-
itional subjects (6 lucerastat and 4 placebo). Thus,
Cohort 1 to 4 received 200, 500, 500, and 1000 mg b.i.d.
lucerastat, respectively. Subjects were admitted to the
clinical unit on Day −1 and received a single dose of
lucerastat or placebo in a fasted state b.i.d. from Day 1
to Day 7, i.e., 14 doses in total. Subjects were discharged
36 h after the last lucerastat dose (on Day 9) and
returned for a follow-up visit on Day 14. Progression to
an increased dose of lucerastat was permitted only after
a satisfactory review of all data from the previous cohort.
Subjects from Cohort 2 participated in the evaluation of
a food effect treatment period before the MAD study
per se. These subjects were admitted to the clinical site
on the morning of the day before dosing as planned for
the MAD study and received a single dose of 500 mg
lucerastat in the morning within 15 min of consuming a
standardized high-fat breakfast, in line with published
guidance on food-drug interactions assessment [14].
Subjects were discharged 24 h after dosing and under-
went a washout period of at least 5 days before re-
admission to the multiple-dose treatment period. Data
from Day 1 of the MAD study were used for the fed vs
fasted comparison. Results of the MAD study are pre-
sented by dose cohort (200, 500, and 1000 mg) except
for the food effect for which Cohort 2 is analyzed
independently.
Clinical supply management
The investigational product (lucerastat) and matching
placebo were manufactured applying appropriate Good
Manufacturing Practice (GMP) standards, and provided
by the sponsor along with a certificate of analysis, in-
cluding expiry or retest date. Lucerastat and placebo
were supplied to the clinical site at least 7 working days
before the start of both studies. The sponsor packaged
the investigational product and matching placebo to pre-
vent contamination or deterioration during transport
and storage. The sponsor determined acceptable storage
temperatures, conditions, and times for the investiga-
tional product and placebo, and informed the clinical
site of these.
Sample collection & bioanalysis
In the SAD study, for the determination of plasma con-
centrations of lucerastat, blood samples were collected
immediately before dosing (0 h) and at 0.5, 1, 1.5, 2, 2.5,
3, 3.5, 4, 6, 8, 10, 12, and 24 h post-dose in all subjects.
In Group 5, additional samples were drawn after the sec-
ond dose following the same sampling scheme as for the
first dose (until the 12 h sample). Lucerastat concentra-
tion was also determined in urine samples collected pre-
dose and 0–4, 4–8, 8–12, and 12–24 h post-dose. In
Group 5, additional urine samples were collected 24–36
and 36–48 h after the first dose.
In the MAD study, for the determination of plasma con-
centrations of lucerastat, blood samples were collected
pre-dose (0 h) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10,
12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 18, 20, 22, and
24 h post-dose on Day 1 and Day 7. Additional blood
samples were drawn at 36 h and 48 h after first lucerastat
intake on Day 7. Further, trough samples were collected
before the morning dose on Day 4 and Day 6. Urine
samples were also collected for lucerastat PK 0–6, 6–12,
12–18, and 18–24 h post-dose on Day 1 and Day 7.
Plasma and urine concentrations of lucerastat were de-
termined using a validated liquid chromatography with
tandem mass spectrometry (LC–MS/MS) assay with a
lower limit of quantification (LOQ) of 50.0 ng/mL in
plasma and 1 μg/mL in urine. For plasma samples, inter-
run accuracy was between 92.9–102.1% and precision
was < 12.3%. For urine samples, inter-run accuracy was
between 90.7–103.4% and precision was < 15.1%.
Safety assessments
In the SAD study, to assess the safety of lucerastat,
adverse events (AEs) were recorded from the admission
on Day −1 up to the follow-up visit on Day 7. The study
investigator assessed the intensity of each AE and its re-
lationship to the study treatment. For all subjects, on
Day −1, vital signs, clinical laboratory tests, urine drug
screen, and alcohol breath test were performed. Other
safety assessments, i.e., 12–lead ECG and vital signs
were performed pre-dose as well as at 2, 4, 8, and 24 h
post-dose for Groups 1 to 4 and also at 48 h after the
first dose in Group 5. Clinical chemistry was repeated at
24 h post-dose for subjects in Groups 1 to 4, and at 48 h
post-dose for subjects in Group 5.
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In the MAD study, AEs, whose intensity and potential
relationship to lucerastat was evaluated by the investiga-
tor, were reported from Day 1 up to the follow-up visit.
Other safety assessments, including body weight, clinical
laboratory tests, vital signs, renal clearance, urine drug
test, and alcohol breath test, were performed at admis-
sion. Vital signs were assessed pre-dose, at 2, 4, 6, 12,
and 24 h post-dose on Day 1 and Day 7, and at 48 h
post-dose on Day 7. 12–lead ECGs were recorded (i)
pre-dose on Day 1, 3, 5, and 7 (ii) at 2, 4, 12, and 24 h
post-dose on Day 1 and 7 (iii) 48 h post-dose on Day 7.
Clinical laboratory tests were performed pre-dose at
Days 4 and 7, and 48 h after last lucerastat intake on
Day 7. On Day 7, body weight was measured pre-
dose and physical examination was conducted 48 h
post-dose. Because of the well-described gastrointes-
tinal (GI) adverse effects of miglustat [15], stool fre-
quency and consistency were recorded by dose level,
subject, and day.
Pharmacokinetic and pharmacodynamic assessments
In both studies, the plasma PK parameters of lucerastat
were derived by non–compartmental analysis (Phoenix
WinNonlin - version 3.1) of the concentration–time
profiles. All plasma concentration values below the limit
of quantification (BLQ, 50.0 ng/mL) were set to zero as
there were no BLQ values between two quantifiable
values. Reports of BLQ at the end of a concentration-
time profile with no samples at subsequent timepoints
containing quantifiable concentrations were ignored for
PK purposes. Mean concentration–time profiles were
generated using these criteria.
The measured individual plasma concentrations of
lucerastat were used to directly obtain the maximum
observed plasma concentration (Cmax) and the time to
Cmax (tmax). The area under the plasma concentration–
time curve from zero until the last quantifiable concen-
tration (AUC0-t) and AUC0–12, the area under the
plasma concentration–time curve over a dosing interval
(12 h), were calculated according to the linear trapez-
oidal rule, using the measured concentration–time
values above the limit of quantification (LOQ). The area
under the plasma concentration–time curve from zero
to infinity (AUC0–∞) was calculated by combining
AUC0-t and AUCextra. AUCextra represents an extrapo-
lated value obtained by Ct/λz, where Ct is the last plasma
concentration above the LOQ and λz represents the ter-
minal elimination rate constant determined by log–lin-
ear regression analysis of the measured plasma
concentrations in the terminal elimination phase. The
terminal elimination half-life (t1/2) of lucerastat was cal-
culated by regression analysis of the terminal elimination
slope (t1/2 = ln2/λz). Ae was the cumulative amount of
unchanged drug excreted in urine and was evaluated in
both studies.
In the MAD study, Cmax and tmax were determined
after the first dose on Days 1 and 7, and also following
dosing on Day 1 of the food effect session.
Statistical analysis
Summary statistics (i.e., mean, standard deviation [SD],
minimum, maximum, number of subjects [n], and coeffi-
cient of variation) were calculated for plasma concentra-
tions at each timepoint and each dose level. The same
parameters were calculated for urine concentrations in
each collection interval and each dose level on each day.
Summary statistics were presented for all PK parameters
by dose level and day. PK parameters for Cohort 2 were
summarized separately by food status. In addition, geo-
metric means and coefficients of variation (based on
logarithmically transformed data) were presented for
AUC and Cmax by dose level.
Dose proportionality was assessed across lucerastat
doses in the fasted state using the power model de-
scribed by Gough [16], which was applied to the log e
AUC (AUC0–∞ for the SAD study and AUC0–12 for the
MAD study) and Cmax data. A point estimate and 90%
confidence interval (CI) were produced for the popula-
tion mean slope. Approximate dose proportionality was
to be concluded when the 90% CI for the slope was
completely within the equivalence boundaries of (0.90,
1.10) for the SAD study and (0.86, 1.14) for the MAD
study. Equivalence boundaries were calculated according
to the following equation: [1 + ln(ɵL)/ln(dose ratio), 1 +
ln(ɵU)/ln(dose ratio)], using the default boundaries of
bioequivalence (ɵL = 0.8, ɵU = 1.25) as an interval [17].
Additionally, for Cohort 2 in the MAD study, Day 1
Cmax and AUC0–12 values were subjected to ANOVA,
including terms for subject and food regimen, to deter-
mine the effects of food. The differences between fed
and fasted regimen for Cmax and AUC0-t were explored
using ratios of geometric means and their 90% CI with
fasting regimen considered as reference. A linear
mixed–effects model with the group of subjects as a
fixed effect was used for the generation of ratios of geo-
metric means and their 90% CI. Food effect on treat-
ment relative to a fasting regimen was concluded when




In total, 39 subjects were enrolled in the study. All sub-
jects recruited completed the study. The mean (± SD)
age was 29.8 (±7.6) years, the mean weight was 76.4
(±9.8) kg, and the mean height was 178.1 (±7.0) cm.
There was no notable difference in mean age, weight, or
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height between the subjects randomized to placebo and
those randomized to lucerastat. Within the 2 weeks be-
fore screening, 2 subjects were taking multivitamins and
calcium dietary supplements for general health, one sub-
ject was treated with erythromycin for acne, and one
with paracetamol for headaches. The investigator con-
sidered none of these to interfere with the outcome of
the study. During the course of the study, one subject
randomized to 100 mg lucerastat was administered an
analgesic to treat flu symptoms.
During the study, a total of 15 AEs, all of mild inten-
sity, were reported in 10 subjects (Table 1). 2 subjects
who received 1000 mg lucerastat b.i.d. developed a total
of 5 drug-related AEs. 5 other drug-related AEs were
Table 1 Summary of treatment-emergent adverse events by frequency and preferred term






















Number of subjects with at least one AE 2 2 0 1 4 1 9
Total number of AEs 2 2 0 1 9 1 14
Preferred term
Fatigue - - - - 1 - 1
Influenza like illness 1 - - - - - 1
Constipation - - - 1 - - 1
Abdominal upper pain - - - - 1 - 1
Back pain - - - - 1 - 1
Neck stiffness - - - - 1 - 1
Cough - - - - 2 - 2
Hot flushes - - - - - 1 -
Headache - - - - 2 - 2
Paresthesia 1 - - - - - 1
Somnolence - - - - 1 - 1
Rash NOS - 2 - - - - 2
















Number of subjects with at least one AE 3 6 1 5 10
Total number of AEs 3 7 3 5 13
Preferred term
Lymphadenitis submandibular - 1 - - 1
Aphthous stomatitis - - 1 - 1
Constipation 1 - - - 1
Diarrhea - 1 - - 1
Dyspepsia 1 - - 2 1
Toothache 1 - - - 1
Nasopharyngitis - 1 - - 1
ALT increased - 3 - 1 3
AST increased - 1 - - 1
Dizziness - - - 1 -
Headache - - 1 - 1
Rash NOS - - 1 1 1
AE Adverse Events, Coding details according to MedDRA version 14.0; NOS Not otherwise specified
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observed in subjects who received placebo (1 AE),
100 mg (2 AEs), or 300 mg lucerastat (2 AEs). All were
considered to be “possibly” related to study treatment.
The 5 remaining AEs were judged to be unrelated to
study treatment. No SAEs were reported for any subject.
The proportion of subjects with AEs and the number
of AEs was highest after dosing with 1000 mg lucerastat
b.i.d.. However, 4 of the 5 AEs considered by the investi-
gator to be possibly related to lucerastat were reported
after the first dose was given and before the second dose
was administered. There was no correlation between the
time of onset of AEs and tmax. AEs observed in the SAD
study are summarized in Table 1.
No clinically significant changes from baseline were
observed in mean hematology, clinical chemistry or
urinalysis values. A number of individual values were
above or below the reference range but none were con-
sidered clinically significant. All post–dose urinalyses
were reported as normal. There was no notable mean
change from baseline in any vital sign or ECG parameter
assessed and no individual subject value was considered
clinically significant. All ECGs recorded during the study
were reported as “Normal” or “Abnormal but not clinic-
ally significant”. A change from baseline in physical
examination was noted for one subject who reported a
fine macular rash in the 300 mg group. This AE resolved
without sequelae in the absence of treatment.
Administration of increasing doses of lucerastat re-
sulted in a dose-dependent increase in lucerastat plasma
concentration (Fig. 1). Peak plasma concentrations of
lucerastat were attained between 1.00 and 4.00 h after
dosing. In Group 5, in which subjects received two doses
of lucerastat 12 h apart (Table 2), 2 subjects reached tmax
2.00 and 2.50 h after the second dose. tmax exhibited no
consistent trend with increasing dose, with median
values of 1.25, 2.00, 2.75, 2.25, and 2.00 h for Group 1 to
5, respectively. The range of geometric means of t1/2 of
lucerastat was 4.43 to 6.47 h among all groups. Lucera-
stat showed no evidence of accumulation in Group 5 as
the second dose of 1000 mg did not result in a higher
Cmax than the first dose given 12 h earlier (Table 2).
Data analysis for dose proportionality showed that the
90% CI for the population mean slope was entirely
within the acceptance range (0.90, 1.10) for AUC0–∞
(0.94, 1.08) and was slightly out of range for Cmax (0.85,
1.08), suggesting that there was a dose-proportional in-
crease in both variables across the doses tested. Absolute
Cmax and AUC0–∞ values are presented in Table 2.
The amount of unchanged drug excreted in urine (Ae)
over 12 h after dosing increased in proportion to dose.
Mean estimates (SD) were 47 (21), 145 (52), 256 (24),
452 (122), 524 (50) mg, for Group 1 to 5, respectively.
Ae data over 12 and 24 h are summarized in Table 3.
MAD study
In total, 37 subjects were randomized in the study. All
37 subjects received one or more doses of lucerastat or
placebo. One subject was withdrawn from the study in
the 500 mg cohort after the morning dose on Day 6 be-
cause of increased ALT and AST levels not associated
with a bilirubin increase (recorded as moderate and mild
severity AEs, respectively, both considered as possibly
related to the study drug and above 3 times the upper
limit of normal [ULN]). This subject completed the food
effect treatment period before beginning the multiple–
dose treatment period. All other subjects completed the
study. The mean (± SD) age was 27.6 (±6.9) years, the
mean weight was 76.1 (±10.4) kg, and the mean height
Fig. 1 Arithmetic mean plasma concentration–time profiles of lucerastat in healthy subjects after administration of a single oral dose of
100, 300, 500, and 1000 mg lucerastat, or two oral doses of 1000 mg lucerastat separated by 12 h (linear and semilogarithmic scales,
0–48 h). (Per–protocol set)
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was 179.0 (±6.7) cm. There were no clinically significant
differences in mean age, height, weight, or BMI between
subjects receiving lucerastat or placebo in any of the
dose cohorts. None of the medications taken in the
2 weeks before Screening were considered by the Princi-
pal Investigator to influence the outcome of the study,
none prevented a subject from entering the study, and
all were stopped before the study. During the study, one
subject of the 500 mg cohort received 1 g paracetamol
to treat cold symptoms.
Eighteen AEs were reported in 15 subjects throughout
the study, all but two were considered to be mild in
severity. The remaining two AEs were considered to be
moderate. One subject in Cohort 2 had nasopharyngitis
that was considered to be moderate in severity and unre-
lated to study drug. This AE began during the food
effect treatment and was on-going during the multiple–
dose treatment period and resolved without treatment
on Day 5. Another subject in Cohort 2 had increased
ALT of moderate severity on Day 4 that was considered
possibly related to the study drug. Study drug
administration was discontinued for this subject after
the morning dose on Day 6, when he presented mild
severity increase in AST, and was withdrawn from the
study on Day 7. In Cohort 2, AEs of increased ALT were
recorded in 4 of the 6 subjects (including 1 subject
receiving placebo) and all were considered to be possibly
related to the study drug. As ALT/AST increased be-
tween 2.0–6.1 and 1.2–4.0 fold from baseline in subjects
of Cohort 2 for whom AEs of elevated ALT/AST were
reported, it was decided to repeat the 500 mg cohort
(Cohort 3) before the 1000 mg cohort was dosed. No
ALT/AST increase was observed in Cohort 3. Other AEs
considered as possibly related to study drug by the
investigator were dyspepsia, diarrhea, aphtous stomatitis,
dizziness, headache, and skin rash. A slightly higher pro-
portion of subjects with drug-related AEs was reported
for subjects dosed with lucerastat compared to placebo-
dosed subjects in all dose cohorts (37.5% vs 30.7%)
except for Cohort 3 (75.0% vs 16.7%). There was no evi-
dence of an increasing incidence of drug-related AEs
with increasing doses of lucerastat. AEs are summarized
Table 2 Plasma pharmacokinetic variables of lucerastat
Study Dose regimen Cmax [μg/mL] tmax [h] AUC0–12 [μg · h/mL] AUC0–∞ [μg · h/mL] t1/2 [h]
SAD 100 mg 1.07 [0.83, 1.39] 1.25 [1.00, 3.00] 4.85 [4.13, 5.69] 5.67 [4.77, 6.71] 4.43 [3.59, 5.46]
300 mg 2.95 [2.17, 4.01] 2.00 [1.50, 4.00] 19.12 [16.27, 22.46] 19.75 [16.81, 23.20] 4.98 [4.65, 5.33]
500 mg 4.27 [3.75, 4.85] 2.75 [1.50, 3.50] 26.11 [22.94, 29.72] 27.27 [24.13, 30.83] 5.70 [5.11, 6.36]
1000 mg 10.31 [6.62, 16.05] 2.25 [1.00, 3.50] 57.81 [45.07, 74.14] 60.09 [47.26, 76.41] 5.40 [4.70, 6.22]
2x1000 mg 10.52 [7.50, 14.74] 2.00 [1.50, 2.50] 116.374 [94.74, 142.96]1 118.01 [95.96, 145.12] 6.47 [5.42, 7.72]
MAD 200 mg Day 1 1.99 [1.61, 2.47] 2.00 [1.00, 3.00] 9.18 [7.35, 11.48] 22.77 [19.26, 26.92] 6.10 [4.78, 7.78]
Day 7 2.33 [1.68, 3.24] 2.00 [1.50, 3.50] 11.59 [9.72, 13.83] 28.07 [24.69, 31.91] 5.88 [4.68, 7.39]
500 mg Day 1 4.82 [4.41, 5.26] 2.50 [1.50, 3.50] 23.20 [20.84, 25.83] 56.87 [50.94, 63.50] 5.84 [4.88, 6.99]
Day 7 5.18 [4.54, 5.90] 2.50 [0.50, 3.50] 29.37 [25.36, 34.00] 65.83 [56.70, 76.42] 6.33 [5.55, 7.21]
1000 mg Day 1 11.39 [9.06, 14.34] 2. 50 [1.50, 3.00] 51.67 [47.47, 56.24] 121.62 [112.03, 132.03] 5.41 [4.05, 7.23]
Day 7 11.10 [8.69, 14.19] 2.50 [1.50, 4.00] 59.84 [50.97, 70.24] 132.02 [113.28, 153.87] 6.83 [5.76, 8.10]
Data are geometric means (95% CI), except for tmax, for which medians (range) are given. Cmax maximum plasma concentration, tmax time to reach maximum
plasma concentration, AUC0–12 area under plasma concentration–time curve over a dosing interval (12 h),
1area under plasma concentration–time curve from zero
to 24 h; AUC0–∞ area under plasma concentration–time curve from zero to infinity, t1/2 terminal half–life, CI confidence interval, SAD single ascending dose, MAD
multiple ascending dose
Table 3 Urine pharmacokinetic variables of lucerastat
Study Dose regimen Ae 0-12h [21] Ae 12-24h [21] Ae 0-24h [21] % of dose
SAD 100 mg 47 (21) 6 (4) 53 (24) 53 (24)
300 mg 145 (52) 10 (6) 153 (54) 49 (20)
500 mg 256 (24) 24 (12) 280 (12) 56 (6)
1000 mg 452 (122) 49 (46) 501 (98) 50 (10)
2x1000 mg 524 (50) 304 (191) 904 (295) 45 (15)
MAD 200 mg Day 7 160 (14) 145 (31) 305 (40) 76 (10)
500 mg Day 7 357 (64) 362 (56) 719 (101) 72 (10)
1000 mg Day 7 864 (243) 830 (152) 1695 (289) 85 (15)
Data are arithmetic means (standard deviation); Ae cumulative amount of unchanged drug excreted in urine, SAD single ascending dose, MAD multiple
ascending dose
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in Table 1. No SAEs were reported for any subject. No
clinically significant changes from baseline were ob-
served regarding vital signs, ECG, hematology, and
clinical chemistry (except for AST and ALT elevations
mentioned above). An abnormal, clinically significant
urinalysis result was reported in a subject who had a
trace of blood and of leucocytes in the urine on Day 4.
However, this result was not considered an AE by the
investigator as the microscopy result was normal, and as
the subject had an abnormal, not clinically significant,
urinalysis result at admission. A higher proportion of
subjects with 2 or more stool samples per study day was
observed in Cohorts 2 and 3 compared to subjects
receiving placebo or any other dose of lucerastat. How-
ever, there was no evidence of an increase in the propor-
tion of subjects with ≥ 2 stool samples over the whole
study period.
Multiple-dose administration of lucerastat resulted in
a dose-dependent increase in lucerastat plasma concen-
tration (Fig. 2).
In the 200 mg cohort, tmax occurred between 1.00 and
3.50 h after the second daily dose in 5 out of 6 subjects
on Day 1 and Day 7. Median tmax was 2.50 h in the
500 mg and 1000 mg b.i.d. dose cohorts, both on Day 1
and Day 7, occurring after the second dose in only one
subject. Systemic exposure to lucerastat increased by up
to 1.3-fold between Day 1 and Day 7. The time to reach
steady state can be inferred from 4 to 5 multiples of t1/2
calculated from Day 1 values as approximately 30 h.
Thus, steady state was attained on Day 7 of dosing, as
confirmed by the pre-dose lucerastat levels on Day 4, 6,
and 7. For instance, mean lucerastat plasma trough con-
centration (± SD) was 2.17 (±0.24), 2.12 (±0.41), and
2.05 (±0.27) μg/mL on Day 4, 6, and 7, respectively.
Analysis of the data from Day 7 for dose proportional-
ity showed that the 90% CI for the population mean
slope was entirely within the acceptance range (0.86,
1.14) for AUC0–12 (0.91, 1.13) and was slightly out of
range for Cmax (0.82, 1.10), suggesting that there was a
dose-proportional increase in both variables across the
doses tested. Ae over 24 h after dosing on Day 7 in-
creased in proportion to dose. Mean Ae estimates (SD)
were 305 (40), 719 (101), and 1695 (289) mg, for the
200, 500, and 1000 mg dose groups, respectively. Ae data
over 12 and 24 h are summarized in Table 3.
GMR of Cmax and AUC0–12 values of Day 1 were cal-
culated to compare the fed and fasted regimens for
500 mg lucerastat (Cohort 2). Cmax was greater after
dosing in the fasted state than after dosing in the fed
state, as indicated by a GMR of 0.76 (90% CI: 0.61, 0.94).
Total systemic exposure to lucerastat on Day 1 was simi-
lar following dosing in the fasted and fed states, with an
adjusted GMR of 0.93 (90% CI: 0.80, 1.07). Median
values for tmax were similar after dosing in the fed and
the fasted regimen (2.75 h). Ae was also similar after
dosing in both the fasted and fed state, with mean (SD)
Ae from 0 to 12 h in fasted state of 433 (148) mg vs 403
(143) mg in the fed state.
Discussion
Lucerastat was well tolerated in both studies. In the
SAD study, there was no difference in the proportion of
subjects with drug-related AEs after any treatment, al-
though the number of AEs was highest in the subjects
dosed with 1000 mg b.i.d. There was no correlation be-
tween the time of onset of AE and lucerastat plasma ex-
posure. Lucerastat was considered to be safe following
multiple dosing with 200, 500, and 1000 mg b.i.d. for
7 days and as a single 500 mg dose in the fed state.
Increases from baseline in ALT/AST concentrations
were observed in 500 mg lucerastat-dosed subjects
within Cohort 2 as well as in a placebo-dosed subject.
Fig. 2 Arithmetic mean plasma concentration–time profiles of lucerastat in healthy subjects on Day 7 after multiple-dose administration of 200,
500, and 1000 mg lucerastat b.i.d. (intakes separated by 12 h, linear and semilogarithmic scales, 0–48 h). (Per–protocol set)
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Elevated ALT levels, observed 4 times in Cohort 2, are
more specific for liver damage than AST elevations [18],
which was reported only one time in the same cohort.
Due to the elevations of liver transaminases in the
500 mg b.i.d. Cohort 2, it was decided to repeat this dose
level. No notable increases in ALT or AST levels were
detected in the subjects in Cohort 3. As the incidence of
elevated ALT levels was similar in placebo- and
lucerastat-dosed subjects in Cohort 2, it was most likely
due to the relative inactivity of the subjects and weight
gain during the residential period as described previ-
ously. It is known that transaminase increases occur in
residential studies also in subjects receiving placebo. In a
pooled population from 13 phase I studies, 7.5% of 93
subjects who received placebo presented at least 1 value
of ALT that was twice ULN, and 20.4% had at least 1
value above ULN [19]. In the MAD study only 1 subject
had an ALT increase > 2 x ULN, i.e., 2.7% of the popula-
tion of the study, and 10 subjects had at least 1 ALT
value above ULN (27% of the subjects enrolled). There-
fore, greater attention was paid to the need for regular
exercise and prevention of weight gain in Cohort 3 and
4, and the subjects in these cohorts were weighed daily.
As there was no ALT/AST increase in these last 2 co-
horts and taking into account the role of residential
studies in increasing ALT levels in healthy subjects,
there was no safety concern regarding elevation of liver
transaminases caused by lucerastat in these 2 studies.
These data are to be confirmed in studies with larger
numbers of patients.
The GI tolerability of lucerastat was good, in con-
trast to that of miglustat. There was no effect of in-
creasing dose or multiple dosing of lucerastat on
stool frequency or on the incidence of GI AEs in
healthy subjects. The good GI tolerability of lucerastat
has been corroborated in chronic toxicology studies
in rodents and dogs (data on file). This differentiation
in GI tolerability between the two structurally related
compounds can be explained by the fact that lucera-
stat is a galactose analog iminosugar which does not
inhibit intestinal sucrase-isomaltase. Miglustat is a
glucose analog iminosugar and a potent inhibitor of
sucrase-isomaltase [7, 15].
In the SAD study, the systemic exposure to lucerastat
(as indicated by Cmax and AUC0–∞) increased propor-
tionally as the dose was increased from 100 to 1000 mg.
This indicates the absence of saturation of absorption or
elimination mechanisms, also at high doses. Dose-
related increase in systemic exposure was confirmed in
the MAD study, for which dose proportionality was con-
cluded statistically regarding AUC0–12. All other PK
parameters reported were independent of dose. The PK
of lucerastat showed relatively low intersubject variabil-
ity and did not change with time.
The fraction of administered dose excreted as un-
changed drug in urine was high, suggesting that renal
elimination of lucerastat is the most relevant route of ex-
cretion. This had also been seen in previous preclinical
ADME studies with radiolabeled lucerastat (data on file)
in which excretion of radioactivity via urine was pre-
dominant (60% in rats and 67% in dogs), similarly to
what was observed with miglustat in rats [20]. Cmax and
AUC0–12 values were similar following dosing in the
fasted and fed states. Thus, food intake did not affect the
total systemic exposure to lucerastat, which may be
taken without regard to meals.
In the MAD study, lucerastat plasma concentration
was equal to or above the Ki for GCS inhibition for 50%
and 80% of the dosing interval at doses of 500 and
1000 mg b.i.d., respectively, which is deemed to be
adequate to achieve SRT in patients with GLSDs.
Conclusion
In conclusion, oral lucerastat was well tolerated in terms
of AEs, in particular GI tolerability, and with respect to
all safety variables assessed. Based on the favorable
safety, tolerability, and PK results of lucerastat in healthy
subjects, the potential of lucerastat as SRT was assessed
in an exploratory study in subjects with Fabry disease in
which safety was evaluated, and plasma and urine levels
of several glycosphingolipids were measured (Identifier
NCT02930655). The results of this study will be
reported separately (21).
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